ARVEE

Arvee Laboratories (India) Share Price

₹162.20 -2.8 (-1.7%)

24 Jun, 2025 21:27

SIP TrendupStart SIP in ARVEE

Start SIP

Performance

  • Low
  • ₹162
  • High
  • ₹168
  • 52 Week Low
  • ₹127
  • 52 Week High
  • ₹236
  • Open Price₹168
  • Previous Close₹165
  • Volume42

Investment Returns

  • Over 1 Month -4.98%
  • Over 3 Month + 4.68%
  • Over 6 Month -6.98%
  • Over 1 Year -14.63%
SIP Lightning

Smart Investing Starts Here Start SIP with Arvee Laboratories (India) for Steady Growth!

Invest Now

Arvee Laboratories (India) Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 83.2
  • PEG Ratio
  • 0.8
  • Market Cap Cr
  • 179
  • P/B Ratio
  • 5.7
  • Average True Range
  • 9.46
  • EPS
  • 1.95
  • Dividend Yield
  • 0
  • MACD Signal
  • 3.29
  • RSI
  • 45.21
  • MFI
  • 22.51

Arvee Laboratories (India) Financials

Arvee Laboratories (India) Technicals

EMA & SMA

Current Price
₹162.20
-2.8 (-1.7%)
pointer
  • stock-down_img
  • Bearish Moving Average 11
  • stock-up_img
  • Bullish Moving Average 5
  • 20 Day
  • ₹169.05
  • 50 Day
  • ₹163.44
  • 100 Day
  • ₹160.31
  • 200 Day
  • ₹161.73

Resistance and Support

164.27 Pivot Speed
  • R3 172.53
  • R2 170.47
  • R1 166.33
  • S1 160.13
  • S2 158.07
  • S3 153.93

What's your outlook on Arvee Laboratories (India)?

You can only vote once!

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Arvee Laboratories (India) has an operating revenue of Rs. 38.49 Cr. on a trailing 12-month basis. An annual revenue growth of 26% is outstanding, Pre-tax margin of 7% is okay, ROE of 6% is fair but needs improvement. The company has a reasonable debt to equity of 3%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 200DMA and close to its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 23 which is a POOR score indicating inconsistency in earnings, a RS Rating of 55 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C+ which is evident from recent supply seen, Group Rank of 32 indicates it belongs to a strong industry group of Chemicals-Specialty and a Master Score of C is fair but needs to improve. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Arvee Laboratories (India) Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-05-09 Audited Results & Others To consider Other business matters. issue in the ratio of 1:1 of Rs. 10/-.
2025-02-12 Quarterly Results
2024-11-14 Quarterly Results & Others To consider other business matters. issue in the ratio of 1:1 of Rs. 10/-.
2024-08-13 Quarterly Results
2024-02-13 Quarterly Results (Revised) issue in the ratio of 1:1 of Rs. 10/-.

Arvee Laboratories (India) F&O

Arvee Laboratories (India) Shareholding Pattern

73.5%
26.32%
0.18%

About Arvee Laboratories (India)

  • NSE Symbol
  • ARVEE
  • BSE Symbol
  • Managing Director
  • Mr. Shalin Sudhakarbhai Patel
  • ISIN
  • INE006Z01016

Similar Stocks to Arvee Laboratories (India)

Arvee Laboratories (India) FAQs

Arvee Laboratories (India) share price is ₹162 As on 24 June, 2025 | 21:13

The Market Cap of Arvee Laboratories (India) is ₹178.7 Cr As on 24 June, 2025 | 21:13

The P/E ratio of Arvee Laboratories (India) is 83.2 As on 24 June, 2025 | 21:13

The PB ratio of Arvee Laboratories (India) is 5.7 As on 24 June, 2025 | 21:13

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23